High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia
E. J. Chory, M. Wang, M. Ceribelli, A. M. Michalowska, S. Golas, E. Beck, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, S. Divakaran, J. Bradner, J. Khan, B. E. Gryder, C. J. Thomas, B. Z. Stanton
Abstract
We report a comprehensive drug synergy study in acute myeloid leukemia (AML). In this work, we investigate 11 cell lines spanning both MLL-rearranged and non-rearranged subtypes. The work comprises a resource for the community, with many synergistic drug combinations that could not have been predicted a priori, and open source code for automation and analyses. We base our definitions of drug synergy on the Chou-Talalay method, which is useful for visualizations of synergy experiments in isobolograms, and median-effects plots, among other representations. Our key findings include drug synergies affecting the chromatin state, specifically in the context of regulation of the modification state of histone H3 lysine-27. We report open source high throughput methodology such that multidimensional drug screening can be accomplished with equipment that is accessible to most laboratories. This study will enable preclinical investigation of new drug combinations in a lethal blood cancer, with data analysis and automation workflows freely available to the community. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC="FIGDIR/small/518409v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@1e85ef9org.highwire.dtl.DTLVardef@b3369eorg.highwire.dtl.DTLVardef@1c6d705org.highwire.dtl.DTLVardef@14ec6b2_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines
Fatma Neslihan Kalkan, Muhammed Sadik Yildiz, … Erdal Toprak·Scientific ReportsPeer-reviewed·Jun 3, 2025
- Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
M. Mirzaie, E. Gholizadeh, … M. Jafari·bioRxiv·May 25, 2023
- Patient-tailored design of AML cell subpopulation-selective drug combinations
Aleksandr Ianevski, Jenni Lahtela, … Tero A. Aittokallio·Science AdvancesPeer-reviewed·Feb 19, 2021
- Facilitating the design of combination therapy in cancer using multipartite network models: Emphasis on acute myeloid leukemia
Mohieddin Jafari, Mehdi Mirzaie, … Jing Ping Tang·Nature CommunicationsPeer-reviewed·Apr 19, 2022
- Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML
J. M. Kelvin, J. Jain, … E. C. Dreaden·bioRxiv·Mar 13, 2023
- Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility Alterations
Elham Gholizadeh, Ehsan Zangene, … Mohieddin Jafari·Nature CommunicationsPeer-reviewed·Mar 25, 2026